Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04473326 · ClinicalTrials.gov registry record · NA
Reinforcement Learning in Diabetes Mellitus Trial
A NA study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT04473326 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 60 participants.
The verdict
NCT04473326, a NA study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
Reinforcement learning is an advanced analytic method that discovers each individual's pattern of responsiveness by observing their actions and then implements a personalized strategy to optimize individuals' behaviors using trial and error. The goal of this pilot study is to develop and test a novel reinforcement learning-enhanced text messaging program to support medication adherence in patients with type 2 diabetes. Type 2 diabetes is an optimal condition in which to test this program, as it is one of the most prevalent chronic conditions in the US adult population and requires most patients to be on daily or twice daily doses of medications. This pilot study will be a parallel randomized pragmatic trial comparing medication adherence and clinical outcomes for adults aged 18-84 with type 2 diabetes who are prescribed 1-3 daily oral medications for this disease. Participants will be randomized to one of two arms for the duration of the study period: (1) a reinforcement learning intervention arm with up to daily, tailored text messages based on time-varying treatment-response patterns; or (2) a control arm with up to daily, un-tailored text messages. Our outcomes of interest will be medication adherence, as measured by electronic pill bottles, and HbA1c levels.
Interventions
- BEHAVIORAL Reinforcement Learning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-02-04 |
| Est. Completion | 2022-01-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04473326
The ClinicalTrials.gov registry entry for NCT04473326 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Reinforcement Learning is the first listed.
NCT04473326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04473326 about?
NCT04473326 is a clinical study titled "Reinforcement Learning in Diabetes Mellitus Trial". Reinforcement learning is an advanced analytic method that discovers each individual's pattern of responsiveness by observing their actions and then implements a personalized strategy to optimize individuals' behaviors using trial and error. The goal of this pilot study is to develop and test a nove...
What is the current status of trial NCT04473326?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2021-02-04. Estimated completion is 2022-01-28.
What interventions are being tested in trial NCT04473326?
The interventions under investigation include: Reinforcement Learning (BEHAVIORAL).
Who is sponsoring clinical trial NCT04473326?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.